StreetAlpha.app
Home › Stocks › ACET

Adicet Bio, Inc. (ACET)

$2.78
▲ +1.09%
LAST CLOSE · NOV 17

Adicet Bio develops gamma delta T cell therapies made from donor cells for autoimmune diseases and cancer. It last closed at $2.78 on Nov 17, up 1.09% on the day. The average 12-month price target from 3 analysts is $39.00 (+1302.9% from the last close), with a high of $55.00 and a low of $28.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).

AI Auto Pilots
Is ACET in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$91.0M
EPS (diluted)
−$7.47
Free cash flow
−$80.4M
Valuation
Market cap
$26.0M
9.4M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$27.1M
At Sep 30
Shareholder equity
$102.7M
Shares outstanding
9.4M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$62.0M−$62.0MFY2021FY2022: −$69.8M−$69.8MFY2022FY2023: −$142.7M−$142.7MFY2023FY2024: −$117.1M−$117.1MFY2024FY2025: −$116.8M−$116.8MFY2025

From ACET's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on ACET in the past 90 days
Average 12-month target
$39.00
▲ 1302.9% upside

Based on 3 analysts who set a price target on ACET in the past 90 days. The average target is $39.00, with a high of $55.00 and a low of $28.00, compared with the last close of $2.78.

Low $28.00Avg $39.00High $55.00
Blue marker: last close $2.78
Highest target$55.00
Average target$39.00
Lowest target$28.00
Latest rating changes
GuggenheimTarget lowered
Nov 6Buy$90 → $55
WedbushMaintained
Sep 29Buy$28
HC Wainwright & Co.Target raised
Sep 28Buy$27 → $34
HC Wainwright & Co.Reiterated
Sep 18Buy$27
GuggenheimMaintained
Aug 6Buy$90
DateFirmActionRatingPrice target
Nov 6GuggenheimTarget loweredBuy$90 → $55
Sep 29WedbushMaintainedBuy$28
Sep 28HC Wainwright & Co.Target raisedBuy$27 → $34
Sep 18HC Wainwright & Co.ReiteratedBuy$27
Aug 6GuggenheimMaintainedBuy$90
Loading…

Technical Analysis

ACET · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 20% below its 20 day and 104% below its 50 day average. It is 165% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 19), oversold. The nearest support is the Pivot at $2.75, and the nearest resistance the Pivot R1 at $2.84.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 11.3%/day
Key levels
$11.1552 week high+301.1%
$8.37Swing high (Jun 15)+201.1%
$7.37200 day average+165.1%
$7.20100 day average+159.0%
$5.6650 day average+103.6%
$3.3520 day average+20.5%
$2.84Pivot R1+2.2%
$2.78Last close
$2.75Pivot−1.1%
$2.70Pivot S1−2.9%
$2.6052 week low−6.5%
Indicators
RSI (14)18.56Oversold below 30Oversold
MACD-0.78Above its signal lineBullish
Stochastic10.1Near the bottom of its rangeOversold
ADX (14)67.6Strong downtrend
Williams %R-85.7Oversold below −80, overbought above −20Oversold
CCI (20)-89.4Oversold below −100, overbought above 100Neutral
Rate of change−12.3%Change over 10 sessionsBearish
ATR (14)$0.31Typical daily range, 11.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ACET

What happened before

See how ACET did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ACET usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ACET has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ACET in the last 90 days.

Loading…

See today’s whale options flow across the market →

ACET Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bearish
Strongly bearishNeutralStrongly bullish
  • ▼19 buying vs 25 selling
  • ▼Held by funds -3.7 pts
  • ▼Funds holding -2
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding5456−3.6%
In funds' top 10220.0%
Held by funds61.5%65.3%−3.7 pts
New / increased5 / 1414 / 18−40.6%
Reduced / sold out18 / 79 / 7+56.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ACET institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ACET is in one of them and how their past ACET trades turned out.

ACET in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ACET in an article yet. Here's the latest on the wider market.

About Adicet Bio

Adicet Bio is a biotechnology company based in Boston, Massachusetts. It develops allogeneic gamma delta T cell therapies, made from donor cells so that they can be stored and given to patients on demand. Its lead candidate is being tested for autoimmune diseases such as lupus, and it is also developing a candidate for prostate cancer. The company's therapies are intended for patients with autoimmune diseases and cancer, and they are still in clinical trials.

Headquarters
Boston, MA